Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JWC, Anderson LF, et al.
2018-09-08 • Lancet
2018-09-08 • Lancet
BACKGROUND Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...
Ndjeka N, Schnippel K, Master I, Meintjes GA, Maartens G, et al.
2018-10-25 • European Respiratory Journal
2018-10-25 • European Respiratory Journal
Background: South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline through a ...
Schnippel K, Ndjeka N, Maartens G, Meintjes GA, Master I, et al.
2018-09-01 • Lancet Respiratory Medicine
2018-09-01 • Lancet Respiratory Medicine
Addition of bedaquiline to treatment for multidrug-resistant tuberculosis was associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Foll...
Berhanu R, Schnippel K, Mohr E, Hirasen K, Evans D, et al.
2016-11-03 • PLOS One
2016-11-03 • PLOS One
OBJECTIVE: We describe baseline characteristics, time to treatment initiation and interim patient outcomes at a decentralized, outpatient treatment site for rifampicin-resistant TB (RR-T...